Stay updated with breaking news from Commercialization Activities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pierre Fabre to Lead Launch and Commercialization Activities for EBVALLO In Europe Following Transfer of European Commission Marketing Authorization from Atara Biotherapeutics EBVALLO is the
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced it has entered into an agreement with Sanofi S.A. to exclusively in-license worldwide rights to two early-stage research programs in sickle cell disease (SCD): one that pursues a novel anti-sickling mechanism and another that leverages a new approach to reduce inflammation and oxidative stress. These mechanisms are distinct and potentially complementary to that of Oxbryta® (voxelotor) tablets, a novel hemoglobin S polymerization inhibitor approved in the Unit...